Primary Myeloid Sarcoma of the Prostate: A Case Report and Literature Review

Table 1

Primary myeloid sarcoma of the prostate.

Case	Age	Symptoms	Hematological diagnosis	Time to progression to AML	Treatment	Outcomes
1 [8]	79	Urinary retention	N/A	N/A	None	Died shortly after TURP
2 [9]	67	Urinary retention	AML-M2 (FAB classification)	7 months	Lymphoma-directed chemotherapy and then remission-induction chemotherapy	Originally misdiagnosed as lymphoma and received CHOP. Started remission-induction chemotherapy at AML relapse and achieved CR. Alive at 19 months after MS diagnosis
3 [10]	32	Dysuria, weight loss, and night sweats	AML-M5 (FAB classification)	3 weeks	Remission-induction chemotherapy	Died 3 months after MS diagnosis
4 [11]	71	Dysuria	AML	4 months	Chemotherapy (unspecified)	CR and further follow-up N/A
5 [12]	71	Dysuria	AML-M2 (FAB classification)	4 months	Remission-induction chemotherapy and then salvage chemotherapy	CR and then relapse with salvage chemotherapy with second CR; died 24 months after MS diagnosis due to brain hemorrhage
6 (present case)	73	Frequency and hesitancy	None	N/A	Remission-induction chemotherapy followed by consolidation	Without progression to AML at 1 year after MS diagnosis

AML: acute myeloid leukemia; CHOP: cyclophosphamide; doxorubicin, vincristine, and prednisone; CR: complete remission; FAB classification: French-American-British classification; MS: myeloid sarcoma; N/A: not available; TURP: transurethral resection of the prostate.